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Abstract
Background: Severe asthma is characterised by a variety of symptoms, which include chronic cough, however the
mechanisms responsible for cough reflex hypersensitivity in asthma remain poorly elucidated. Current asthma
patient-related outcome instruments such as the six-point Juniper Asthma Control Score (ACQ-6) and Asthma
Quality of Life Questionnaire (AQLQ) were not primarily designed to capture cough and its related morbidity in
asthma. The Leicester Cough Questionnaire (LCQ) is a patient-related outcome instrument designed to capture the
health-related quality of life associated with cough. To date the LCQ has not been evaluated in a severe asthma
population.
Methods: We evaluated 262 extensively characterised adult patients with severe asthma attending the Leicester
Severe Asthma Service. All patients had a clinician diagnosis of asthma and objective physiological evidence and
met the ATS/ERS criterion for servere asthma. In all patients we evaluated a) the LCQ distribution and b) the
relationships between the LCQ and ACQ-6, AQLQ, airway inflammation in sputum.
Results: The LCQ demonstrated the following properties; mean: 15.0, standard deviation: 4.54, median: 15.48, and
range: 11.6–19.2. We found a moderate correlation between LCQ and ACQ-6 (r = − 0.605, p < 0.0001) and a LCQ and
AQLQ (r = 0.710, p < 0.0001). There was no relationship between LCQ and log10 sputum percentage eosinophils (%).
Conclusion: A proportion of patients with severe asthma have a significant degree of cough-related morbidity that
appears independent of eosinophilic airway inflammation and is not captured fully by existing asthma patient-reported
outcome instruments. Our preliminary findings suggest that further research is now required to validate the LCQ and




Severe asthma is characterised by suboptimal asthma
control in patients receiving step 4/5 therapy [1] and is
associated with high levels of health care utilisation [2].
Severe asthma is associated with a range of co morbidities
[3] (such as nasal polyps, suboptimal treatment adherence,
as well as treatment refractory and difficult asthma) [1, 4].
Chronic cough is associated with physical and psycho-
logical morbidity [5], however the prevalence of chronic
cough within severe asthma populations has not been
determined, in part due to the lack of well-validated
assessment tools.
Cough reflex hypersensitivity syndrome [6] may
underlie the aetiology of chronic cough but the mecha-
nisms are poorly understood and therapeutic options are
limited. Similarly, the impact of chronic cough on the
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health status of patients with severe asthma is not well
understood as existing asthma patient-related outcome
measures such as the six-point Juniper Asthma Control
Questionnaire (ACQ-6) and Asthma Quality of Life
Questionnaire (AQLQ) were not primarily designed to
capture cough and its related morbidity. There are a
number of tools that can be used to understand and
phenotype cough which include digital cough monitors
[7], cough specific health status questionnaires such as
the Leicester Cough Questionnaire (LCQ) and cough
visual analogue scales [8, 9]. The LCQ is a patient-
reported questionnaire designed to capture the health-
related quality of life of cough and is responsive to
changes in chronic cough [10]. More recently the LCQ
has been used in asthma and chronic obstructive
pulmonary disease (COPD) patients to assess the impact
of gastro-oesophageal reflux disease (GORD) on cough-
related morbidity [11] and has also been validated
against the SF-12 questionnaire in COPD [12]. However
the LCQ has not been evaluated in large carefully
characterised severe asthma populations to date.
We sought to determine the spectrum of cough related
morbidity in a severe asthma population, by measuring
total LCQ and its sub domains and evaluating its relation-
ship with standard asthma related questionnaires (ACQ-6,
AQLQ) and percentage sputum eosinophils (a marker of
the degree of eosinophilc bronchitis –a reported driver of
cough in asthma).
Methods
We evaluated 312 adult patients referred to the Leicester
Difficult Asthma Service, using data from a local clinical
management database. The database included all referral
from primary and secondary care.
The use of data extracted from the local database for the
purposes of research was approved by the Leicestershire,
Northamptonshire, & Rutland Research Ethics Committee
(REC Reference.13/EM/0287) and all patients gave their
written informed consent.
The Leicester difficult asthma service, is a tertiary
referral service for difficult asthma patients in the UK
and receives both local and national referrals to evaluate
patients with difficult to control asthma. The evaluation
includes (i) confirmation of the diagnosis of asthma in
all patients using objective measurements, including
extensive phenotyping assessments (ii) systematic evalu-
ation and treatment of comorbidities e.g., rhinosinusitis,
non-adherence and (iii) evaluation for biological agents
and bronchial thermoplasty after (i) and (ii).
All patients (n = 312) had an expert clinician diagnosis
of asthma and one or more of the following objective
physiological criteria; (i) positive methacholine PC20 ≤
8 mg/ml, (ii) bronchodilator responsiveness of 200 ml
and 12% following the administration of 200 μg of in-
haled salbutamol or (iii) peak flow variation over a two
week period of ≥20% [1].
22/312 patients were excluded from analyses as they
did not have difficult to treat asthma and had milder
disease (GINA treatment steps 1–3).
262/290 patients met the criteria met the American
Thoracic Society/European Respiratory Society consen-
sus criteria for severe asthma [13]. Therefore our final
population for analysis consisted entirely of patients with
severe asthma, defined according to international guide-
lines, all of whom had objective evidence of asthma and
were being assessed and managed in a tertiary severe
asthma centre in the UK.
Phenotyping assessments were performed in the stable
state and in patients that had been free from exacerba-
tions for ≥6 weeks. Patients underwent lung function
measurements, including spirometry [post bronchodila-
tor (400 μg salbutamol via a metered dose inhaler and
spacer)], induced sputum samples for differential cell
count and completed the LCQ, ACQ-6 and AQLQ ques-
tionnaires at a single clinical visit. Due to the association
of cough with reflux and upper airway disease, self-
reported gastrointestinal reflux, defined as the presence
of heartburn, cough, nausea, chest pain or dysphagia
after meals was documented, whilst the presence or
absence of seasonal/perennial rhinitis and nasal polyp-
osis was also recorded.
The LCQ is a nineteen-point questionnaire capturing
three domains; Physical (8 items), Psychological (7
items) and Social (4 items). Each item has a score range
1 to 7. Item scores for each domain are summed and
divided by the total number of items in each domain.
The total LCQ is the sum of all domain scores. The
minimum and maximum achievable LCQ total scores
are 3 and 21 respectively [10]. A lower LCQ score signi-
fies more cough. The LCQ Minimal clinically important
difference (MCID) is 1.3 in chronic cough [14]. The
Global Lung function Initiative (GLI) reference equa-
tions were used to calculate FEV1 Z score. Patients with
abnormal spirometry had an FEV1 standardised residual
of ≤ −1.64.
Statistical analysis
Statistical analysis was performed using SPSS 22 (IBM
Corporation, Somers, NY, USA) and Prism 6 (GraphPad
Software Inc., La Jolla, California, USA). Data were ana-
lysed using Student’s t-test or Mann-Whitney U test for
parametric and non-parametric data respectively and chi
squared test for proportions. The threshold for statistical
significance was set at p < 0.05. Correlations between
continuous variables were calculated using Pearson’s
correlation coefficient.
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Results
The clinical characteristics of the asthma population are
shown in Table 1. The population reported here was
similar to other UK severe asthma populations [15]. We
did not systematically exclude smokers (see Table 1),
however only 3/42 patients with a smoking history ≥ 10
pack years had spirometrically confirmed fixed airflow
obstruction (compatible with ACOS).
Figure 1a-d, shows the LCQ total and domain distribu-
tions. The LCQ demonstrated the following properties:
a) Mean: 15.0, b) Standard deviation: 4.54, c) Median:
15.48, c) IQR: 11.6–19.2, d) Range: 4.0–21, e) 10th
percentile point: 8.20 and f) 90th percentile point: 20.38.
There was a moderate negative correlation between
LCQ and ACQ-6 (r = − 0.605, p < 0.0001) (see Fig. 2b),
and a moderate positive correlation between LCQ and
AQLQ (r = 0.710, p < 0.0001) (Fig. 2a). There was no
correlation between LCQ and log10 sputum eosinophils
(%) (r = −0.106, p = 0.106) or sputum neutrophils (data
not shown). Similar and statistically significant correla-
tions existed between LCQ and ACQ-6/AQLQ in GINA
4 and GINA 5 severe asthma populations respectively
(data not shown).
The female asthma population (62.6%) had an LCQ of
14.9 (10.8–18.7), significantly lower LCQ when com-
pared to males 17.1 (12.8–19.8), p = 0.0055.
Patients with asthma with self-reported gastrointestinal
reflux (47.3%) were more likely to be female (67.7%,
p < 0.0001) and had a significantly lower LCQ com-
pared to patients without self-reported gastrointestinal
reflux [median (IQR): 14.3 (10.8–17.8) vs.16.5 (12.8–
19.7), p = 0.0015]. However there was no significant
difference in LCQ between female patients with asthma
with self-reported gastrointestinal reflux (32.0%) and with-
out self-reported gastrointestinal reflux (30.5%) [median
(IQR): 14.31 (10.9–16.9) vs. 15.83 (10.2–19.5), p = 0.1835].
There was no significant difference in LCQ between
patients with asthma with nasal polyps and patients with
asthma without nasal polyps [median (IQR): 14.7 (10.7–
19.7) vs. 15.5 (11.9–18.8), p = 0.7906]. There was also no
significant difference in LCQ between patients with
asthma with perennial/seasonal rhinitis compared to pa-
tients with asthma without perennial/seasonal rhinitis
[median (IQR): 15.21 (11.6–19.0) vs. 16.36 (15.7–20.0),
p = 0.3680).
There was no significant difference in the total LCQ
score between smokers with ≥10 pack/years and
smokers with <10 pack/years (median (IQR): 15.4 (12.7–
19.8) vs.16.22 (11.3–19.0), p = 0.5755).
Discussion
We have chosen the LCQ, a simple and objective measure
of cough to evaluate the burden of cough in severe asthma
Table 1 Clinical Characteristics of Severe Asthma Population
Asthma population
(n = 262)
Age (years) 54.03 (14.9)
Sex (% male) 37.4
GINA Treatment Stepa 5 (4–5)
Step 4: 124
Step 5: 96
Sputum Eosinophil (%)a 3.5 (0.5-18.75)
% on ICS/LABA combination therapy (number) 94.5 (n = 247)
% on Montelukast (number) 27.1 (n = 71)
% on oral theophylline (number) 32.4 (n = 85)
% on Inhaled Tiotrpoium Bromide (number) 26.0 (n = 68)
% on maintenance oral prednisolone (number) 53.8 (n = 156)
Dose (mg/24 h) in those on Prednisolone 10 (5.0–12.5)a
Self-reported gastrointestinal reflux (%) 49.0
Nasal polyps (%) (number) 26.3 (n = 69)
Perennial/seasonal rhinitis % (number) 58.3 (n = 153)
Smoking history (pack years) 7.2 (2.6–20)
Exacerbations in past year 3 (1.0–6.0)a
ITU admissions in past year 0.0 (0.0–0.0)a
Total ITU admissions 0.0 (0.0–1.0)a
Hospital admissions in past year 0.0 (0.0–1.0)a
Unscheduled GP/A&E visits 3.0 (0.0–7.0)a
Smoking history (pack years) 7.2 (2.6–20)a
Proportion of current: ex smokers Current smokers: n = 19
Ex-smokers: n = 76
% Smoking >10 pack years (number) 16 .0 (n = 42)
Post Bronchodilator FEV1 (% Predicted) 73.33 (35.7)
Post Bronchodilator FVC (% Predicted) 96.6 (154..4)
Post Bronchodilator FEV1/FVC (%) 66.82 (14.6)
GLI FEV1 Z score −1.67 (2.68)
Bronchodilator reversibility (%) 14.13 (19.01)
ACQ-6 scorea 2.50 (1.5–3.5)a
AQLQ scorea 3.83 (3.0–5.1)a
LCQ Total scorea 15.48 (11.6–19.2)a
LCQ Total score (females)a 14.9 (10.8–18.7) [n = 164]
LCQ Total Score (males)a 17.1 (12.8–19.8) [n = 98]
LCQ Total score (smoker <10 pack/years) 16.22 (11.3–19.0)
LCQ Total score (smoker ≥10 pack/years) 15.4 (12.7–19.8)
LCQ Physicala 4.75 (3.6–6.0)a
LCQ Psychologicala 5.57 (4.0–6.7)a
LCQ Sociala 5.38 (3.8–6.8)a
GINA Global Initiative for Asthma, ICS/LABA inhaled corticosteroids/long acting
beta-2 agonist combination therapy, ITU Intensive care unit, GP General practice,
A&E Accident and emergency, FEV1 Forced Expiratory Volume in one second, FVC
Forced Vital Capacity, GLI Global Lung Function Initiative, ACQ-6 Six-point Asthma
Control Questionnaire, AQLQ Asthma Quality of Life Questionnaire, LCQ Leicester
Cough Questionnaire. Data expressed as mean (standard deviation) or amedian
(interquartile range)
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and its relationships to existing asthma patient-related
outcome measures and eosinophilic airway inflammations.
We identified that a significant proportion of patients
with severe asthma demonstrated high levels of cough-
related morbidity as evidenced by the LCQ. The 10th
percentile LCQ (8.20) and median LCQ (15.48) in severe
asthma when compared to other chronic respiratory
conditions including Idiopathic chronic cough [median
(SD): 12.8 (3.7)] [16] and Idiopathic pulmonary fibrosis
(IPF) [mean (SD): 16.16 (3.66)] [17] indicated a similar
degree of cough related morbidity. Although a previous
study reported a median LCQ (range): 20.2 (9.5–1.0)
[11], this particular study assessed patients with varying
degrees of asthma severity, suggesting that our observa-
tions are likely to be confined to patients with severe
asthma.
The LCQ was initially developed to study idiopathic
chronic cough [10]. Existing validated asthma control
and quality of life instruments either have no cough-
related questions (e.g., ACQ) or limited information on
Fig. 1 Distribution of the Leicester Cough Questionnaire. LCQ = Leicester Cough Questionnaire. Panel a: Histogram of the distribution of the
Leicester cough questionnaire, Panel b-d: Histogram of the distribution of Leicester cough questionnaire domains
Fig. 2 The relationships between the Leicester Cough Questionnaire and Eosinophilic airway Inflammation in sputum and Asthma Patient-Related
Outcomes in Severe Asthma. LCQ = Leicester Cough Questionnaire, ACQ-6 = Six-point Asthma Control Questionnaire, AQLQ = Asthma Quality of
Life Questionnaire Panel a: Correlation between the Leicester cough questionnaire and Asthma quality of life questionnaire. Pearson correlation
coefficient: r = 0.710, p < 0.0001. Dashed line represents median. Percentage of subjects in each quadrant is shown. Panel b: Bubble plot representing
correlations between the Leicester cough questionnaire and sputum eosinophils (%) (Pearson correlation coefficient: r = −0.106, p = 0.106) and
Six-point Asthma control questionnaire (Pearson correlation coefficient: r = .0.605, p < 0.0001
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cough related morbidity (e.g., AQLQ -has only one
question cough-related question). We identified only
modest correlations between LCQ and ACQ, AQLQ,
which may suggest that the degree of cough is either
cause or consequence of poor disease control and im-
paired health related quality of life. However further stud-
ies evaluating interventions that are known to modify
asthma control and quality of life would be required to test
whether chronic cough has a causal impact upon asthma
control and quality of life in patients with severe asthma.
Our observations support the role of LCQ as an additional
phenotyping tool in patients with severe asthma.
Gastrointestinal reflux is a common cause of chronic
cough and can coincide with asthma, rendering it a
potential confounder of cough in asthma. Patients with
asthma with self-reported gastrointestinal reflux were
predominately female with a significantly lower LCQ
compared to patients without self-reported gastrointes-
tinal reflux. In support of this observation previous stud-
ies have shown subjects with asthma and concurrent
GORD, had poorer asthma control and impaired cough
–related quality of life [11]. However, there was no sig-
nificant difference in LCQ between female patients with
asthma, with and without self-reported gastrointestinal
reflux. These observations suggest a heightened cough
reflex sensitivity that is independent of reflux in female
patients with severe asthma which has been well
reported previously in female patients with idiopathic
chronic cough [18].
One limitation of our study is that we did not quantify
gastrointestinal reflux using objective measurements,
which is important as reflux is well recognised to be
silent in some patients. We also quantified upper airway
disease due to rhinitis and nasal polyps using self-
reporting, however in our experience self-reported
disease demonstrates a high concordance with nasendo-
scopic findings, suggesting that our observations demon-
strating a lack of association of LCQ with upper airways
disease are valid.
Cough is also a well-recognised symptom in bronchi-
ectasis and it is important to note that qualitative CT
has demonstrated evidence of subclinical bronchiectasis
in a proportion of patients (approximately 30%) with
severe asthma [19]. Therefore the presence of super
added bronchiectasis may have been a potential con-
tributor to cough in this population.
It is believed that chronic cough in asthma may be
related to an eosinophilic bronchitis [20]. Airway
eosinophils are associated with cough in the presence
and absence of airway hyperresponsiveness [20] and
mechanistically eosinophils may interact with muscar-
inic nerves [21] and promote cough reflex hypersensi-
tivity. However, we found no significant relationship
between sputum eosinophils (%) and LCQ.
Recent cough guidelines [6] suggest cough reflex
hypersensitivity syndrome underlies the aetiology of
chronic cough; arising from the hypersensitivity of
airway sensory nerves, and thus may be an underlying
mechanism attributing to cough in severe asthma.
Pharmacological therapies targeting cough reflex hyper-
sensitivity include P2X3 receptor antagonists [22].
Conclusions
We conclude that a significant proportion of patients
with severe asthma have a high degree of cough-related
morbidity that appears independent of eosinophilic air-
way inflammation, is associated with suboptimal disease
control and quality of life. Our preliminary findings sug-
gest that further research is now required to validate the
LCQ and its responsiveness in severe asthma popula-
tions to capture cough-related morbidity.
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